| abstract |
A CRIg variant comprising an amino acid substitution at one or more amino acid positions selected from the group consisting of positions 8, 14, 18, 42, 44, 45, 60, 64, 86, 99, 105 and 110 in the amino acid sequence of SEQ ID NO: 2, which has a binding affinity for C3b increased at least twice with respect to human CRIg of native sequence of SEQ ID NO: 2, and / or which is an inhibitor at least 2 times more potent of the alternative complement pathway than human sequence native CRIg of SEQ ID NO: 2. |